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Research
AbstrACt
background In the UK, general practitioners (GPs) 
are usually the first medical contact for patients with 
suspected giant cell arteritis (GCA). While rare, it is critical 
not to miss, as delayed treatment can lead to significant 
complications including permanent visual loss. To date, 
little is known about the approach and challenges to 
diagnosis and management of GCA by GPs.
Objective To investigate the diagnosis and management 
of patients with suspected GCA in UK general practice.
Design and participants A multimethods approach 
was taken, comprising a postal survey of 5000 randomly 
selected UK GPs and semistructured telephone interviews 
of 24 GPs from across the UK.
setting UK general practice.
results 1249 questionnaires were returned. 879 
responders (70%) indicated that they had diagnosed 
and managed a patient with GCA. A variety of clinical 
features were used to identify GCA. 21.9% suggested 
that they would exclude GCA as a diagnosis if headache 
was absent and around one-third do not routinely initiate 
glucocorticoid treatment prior to referral. Significant 
regional variations in referral pathways were reported. 
Thematic analysis of interview transcripts highlighted fears 
relating to a missed diagnosis of GCA and the non-specific 
nature of early GCA presentation. Accessing specialist care 
was highlighted as challenging by many GPs and that a 
national standard fast-track pathway is lacking to support 
this patient group. Additionally there were significant 
concerns regarding potential adverse effects relating to 
long-term treatment with glucocorticoids.
Conclusion GPs appear to over-rely on headache to 
identify GCA and marked geographical differences in 
management, with conflicting referral pathways and 
difficulties in accessing appropriate services exist in the 
UK. A national standard for fast-tracking patients with 
suspected GCA to relevant specialists would be beneficial 
to improve care and outcomes for patients with GCA.
bACkgrOunD
Giant cell arteritis (GCA) is the most common 
large/medium vessel vasculitis.1 It is strongly 
associated with polymyalgia rheumatica 
(PMR) with an estimated incidence of 1.0 
per 10 000 patient-years.2 Barraclough et al 
estimated that a full-time general practitioner 
(GP) will see one new case of GCA every 1–2 
years, although this will greatly depend on 
practice population demographics.3
Classical presenting features of GCA include 
new-onset headache or head pain (which 
may be unilateral and often temporal), scalp 
tenderness, jaw and tongue claudication, 
constitutional and visual symptoms.1 Usually, 
there is a significant inflammatory response 
with raised inflammatory markers. However, 
it can present atypically which may lead to 
delays in diagnosis and potentially irrevers-
ible complications such as sight loss.4 Once 
GCA is suspected, treatment with high dose 
glucocorticoids (often prednisolone in the 
UK) should be initiated along with early 
specialist referral to confirm diagnosis and 
prevent potential disease complications.1
Patients with suspected GCA are usually 
identified clinically, followed by specialist 
referral for temporal artery biopsy (TAB) 
to confirm diagnosis. However, ultrasound 
scanning has been shown to be a useful and 
non-invasive tool to help diagnose GCA5 
although typical ultrasound features of GCA 
may diminish after just a few days of glucocor-
ticoid treatment, whereas histological features 
strengths and limitations of this study
 ► Multimethods approach, allowing the identification 
of significant challenges relating to giant cell arteritis 
(GCA) management in primary care and subsequent 
in-depth exploration of those issues.
 ► First large study to investigate diagnosis and 
management of GCA in general practice.
 ► Suboptimal response rate and therefore potential 
lack of generalisability of findings although 
responder demographics of the questionnaire study 
relating to age, gender and general practitioner (GP) 
role were comparable to national GP demographics.
 ► Telephone interviews often viewed as inferior to 
face-to-face interviews for qualitative studies.
 ► There is the potential for discrepancies between 
reported behaviour and actual behaviour, this is 
inherent in both survey and interview studies.
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of GCA may still be evident on TAB several months after 
initiation of treatment.6 However, the sensitivity of TAB 
can vary with 13%–19% of patients with typical features 
of GCA having a negative TAB.7
In the UK, GPs are the first point of medical contact for 
most patients. The role of the GP involves maintaining a 
high index of suspicion for the disorder, to initiate early 
therapy and urgently refer to an appropriate specialist for 
diagnostic confirmation.1 Following diagnosis, GPs are 
often key in tapering glucocorticoid treatment as well as 
monitoring and management of glucocorticoid-related 
adverse effects and impact on comorbidity, for example, 
osteoporosis, cardiovascular disease, diabetes and devel-
opment of serious infections.2 8
The aim of this study was to investigate the diagnostic 
challenges and initial and ongoing management of 
patients with GCA by GPs in the UK.
MAteriAls AnD MethODs
Given the potential variation in management practices 
due to multiple influences, such as patient presentation, 
multimorbidity, availability of services and variations 
in practice and local policy, a multimethods approach 
combining two study methodologies was chosen to 
produce a more complete overall description of current 
GP diagnostic and management practices for GCA.9 First, 
a national cross-sectional postal survey of 5000 randomly 
selected UK GPs was undertaken to investigate PMR and 
its closely associated illness of GCA, followed by a semi-
structured telephone interview study with a purposive 
sample of survey responders to investigate in depth the 
challenges of diagnosis and management associated with 
GCA and PMR. The cross-sectional postal survey was 
undertaken first, with the findings used to help develop 
the topic guide for the interview study. This paper pres-
ents the combined findings from the two studies relating 
to GCA.
PMr national cross-sectional postal questionnaire survey
A cross-sectional survey was mailed to a random sample of 
5000 GPs from across the UK identified from the Binley’s 
database. The Binley’s database contains the names and 
addresses of the majority of GPs working in the UK. It 
also contains other forms of information, including the 
type of practice, the practice population size, practi-
tioner seniority and some of the clinical services provided 
(www. binleys. com). An online option for survey comple-
tion was also available through Survey Monkey (https://
www. surveymonkey. com). Non-responders were sent a 
reminder card after 2 weeks and a further survey pack 
after 4 weeks. The survey was closed 6 weeks after the 
second survey pack was sent.
No standard survey instrument exists for assessing diag-
nosis and management of GCA by GPs and so questions 
were specifically developed using current literature and 
guidelines for GCA.1 Questions related to how diagnosis 
was made (signs and symptoms) and how the GP managed 
patients with suspected GCA. A mixture of open and 
closed response questions were used. The questionnaire 
was piloted among GPs, rheumatologists and patients.
Descriptive statistics were generated (mean, SD and 
IQR) using the statistical analysis package SPSS V.22.0 
for closed response questions(IBM). For open response 
questions, a thematic content analysis was used.10
the interview study
Participants in the interview study were purposively 
sampled from responders to the GP survey who had 
agreed to further contact. To reflect as broad a range of 
practitioner experience as possible, sampling was based 
on clinical experience, gender and clinical seniority. The 
qualitative interview study topic guide which was used as a 
guide for topics to discuss, was informed by findings from 
the cross-sectional survey and relevant GCA literature. 
The topic guide was reviewed and refined with feedback 
from GPs, rheumatologists and qualitative researchers. As 
transcripts were reviewed, the topic guide was modified 
to focus on themes identified from early interviews. The 
topic guide was piloted with two GPs and refined within 
the research team. These interviews were not included in 
the data analysis.
Interviews were audio recorded and transcribed 
verbatim using an approved transcription company.11 
The resulting transcripts were screened to remove any 
identifying information. Thematic analysis, as described 
by Braun and Clarke, was used to analyse resulting tran-
script data.12 Analysis of the transcripts was managed 
using NVivo V.10.13 TH performed the analysis and 
an inter-rater exercise was undertaken in which three 
other researchers (SM, SLH, JCR) were asked to inde-
pendently analyse and identify general themes relating to 
a randomly selected interview to compare with findings 
by TH. No changes resulted from this exercise.
results
One thousand two hundred and forty-nine (25%) 
completed questionnaires were received and analysed. 
Eight hundred and seventy-nine (70%) GPs had indicated 
that they had managed a patient with GCA. Responders 
to the survey had a mean age of 44 years (SD 9.25) and a 
mean of 13.5 years since qualifying as a GP. Fifty-two per 
cent were female and the majority were partners (74%), 
with salaried (21%) and locum GPs (3%) comprising the 
remainder. For the qualitative study, 24 GP participants 
were telephone interviewed from various regions across 
the UK. Sixteen participants were female and 15 partici-
pants were GP partners.
Questionnaire survey: initial diagnosis and management
Free text open response questions in the questionnaire 
were used to ask all participants to describe how they 
made a diagnosis of GCA. The results are summarised in 
table 1.
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The predominant reported clinical feature used to diag-
nose GCA was headache, along with visual disturbance 
and scalp tenderness. Survey responders indicated that 
they often used a combination of features when making 
a new diagnosis. Of particular note, however, was that 
21.9% of responders indicated that they only use head-
ache to identify GCA.
Management of GCA can be divided into (1) initial 
treatment and referral and (2) long-term glucocorticoid 
reduction and monitoring. For GPs, initial management 
is intimately associated with diagnosis as patients with 
suspected GCA require urgent specialist referral for 
definitive diagnosis and treatment. Table 2 summarises 
the immediate subsequent actions of GPs who have iden-
tified patients with suspected GCA.
Guidance advises that treatment should not be delayed 
and that appropriate urgent referral for specialist diag-
nostic confirmation should be made.1 Four hundred and 
forty-five responders to the survey (35.6%) indicated 
that they would not routinely initiate glucocorticoid 
treatment prior to referral. However, 78.7% (n=983) 
reported that if they were to initiate treatment, appro-
priate doses of between 40 and 60 mg of prednisolone 
would be prescribed. GP responders indicated that they 
were referring patients with suspected GCA to a variety of 
different specialities using an assortment of referral path-
ways, depending on the geographical location in the UK. 
Table 3 summarises to which specialty survey responders 
refer patients with suspected GCA.
themes identified from the qualitative study
Diagnosis
The two main themes identified from the interview study 
related first to the presenting features of GCA and second 
to fears of missing a diagnosis of GCA.
Presenting features of GCA
When asked about GCA symptoms in the interviews, 
participants often gave textbook descriptions of classical 
features of GCA.
Headache in someone over 55 you think giant cell 
arteritis really, that's my mantra, new different head-
ache, classically unilateral but not always, focused 
around the temple, potentially some tenderness 
there, possibly protruding temporal artery, classical-
ly tender when they're combing their hair, but also 
looking for things like jaw claudication or tongue 
symptoms, […] and obviously the dread of visual dis-
turbance as well really which can be anything real-
ly. GP6 (20, F, P)i
While textbook descriptions of classical GCA were 
given, there was recognition that some of these features 
may be difficult to recognise or link to GCA.
jaw claudication is interesting, because I know at the 
time, my colleague and myself, kind of, looked a bit 
more up about GCA and he said, ‘I’ve never heard of 
jaw claudication. GP15 (25, F, P) 
Fear of missing case of GCA
GPs expressed considerable fear about missing a diag-
nosis of GCA given the potential for irreversible visual 
loss.
i Key: GP identifier (time qualified as a GP (years), gender (male/
female), seniority/role (S, salaried; P, partner;)).
Table 1 The features used by responders to identify GCA
GCA feature Theme frequency
Headache/head symptoms 1071
Visual disturbances 671
Scalp (including temporal artery 
tenderness)
468
Jaw symptoms 420
PMR symptoms 69
Systemic symptoms 65
Fatigue 29
Joint/muscle symptoms 20
Tongue symptoms 12
GCA, giant cell arteritis; PMR, polymyalgia rheumatica. 
Table 2 Actions undertaken by GPs with patients with 
suspected GCA
Action n (%) 
Urgent blood tests, initiate treatment and refer 
for outpatient review urgently, if blood tests 
positive
554 (44.4)
Refer to hospital immediately without 
investigation
244 (19.5)
Urgent blood tests and refer to hospital 
immediately if positive
201 (16.1)
Urgent blood tests, initiate treatment and refer 
for outpatients review routinely
66 (5.3)
GCA, giant cell arteritis; GP, general practitioner. 
Table 3 Specialties to which patients with GCA are referred
Specialty Frequency (%)
Rheumatology 478 (38.3)
Ophthalmology 366 (29.3)
General medicine 144 (11.5)
Accident and emergency 35 (2.8)
Neurology 12 (1.0)
Elderly care 9 (0.7)
Other 41 (3.3) 
Missing 164 (13.1) 
GCA, giant cell arteritis. 
group.bmj.com on April 16, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Helliwell T, et al. BMJ Open 2018;8:e019320. doi:10.1136/bmjopen-2017-019320
Open Access 
I find it, sort of, trickier, I think, to diagnose. I worry 
about it more. I worry about missing it. And I feel far 
less confident about treating it. I think when I was 
first qualified as a GP I think I thought somebody had 
got it every week. Anybody who’d got a headache, you 
know. GP24 (12, F, S)
Fears surrounding missing a diagnosis of GCA also 
related to the potential for a wide range of symptoms and 
atypical presentations.
Just with a vague headache, and hadn’t had any vi-
sual disturbance at that point in time. And he didn’t 
really have a lot of temporal artery tenderness. […] 
We did some bloods at that point, and the ESR and 
CRP were normal […]… I wrote in the notes at the 
time, ‘Excludes GCA’…which, having read a bit more 
about it since, after this happened, doesn’t totally ex-
clude it. GP15 (25 , F, P) 
Management
Two main themes were identified from the interview 
transcripts. First, initial and ongoing treatment and 
monitoring and second, referral for definitive diagnostic 
confirmation by a specialist.
Initial and ongoing treatment
Most participants indicated that they would initiate 
patients with suspected GCA on appropriate doses of 
prednisolone.
I think the rheumatologists would say start the 60[mg] 
and I will see them in clinic. GP4 (6, M, P) 
However, there was recognition that treatment could 
impact on the sensitivity of the TAB, especially if it was 
going to be delayed.
what then happens in secondary care, it's less than 
ideal, they seem to rotate who might do a temporal 
artery biopsy between vascular, ophthalmology and 
general surgery […] but the patient generally is hav-
ing that temporal biopsy before ever seeing a rheu-
matologist and the timeliness of that temporal artery 
biopsy is not ideal. GP6 (20, F, P) 
Local policy also had a significant impact on how 
patients with suspected GCA were initially treated. This, 
as well as concerns surrounding the impact that treat-
ment could have on biopsy effectiveness, may account 
for some of the significant number of participants who 
indicated that they would not initiate treatment prior to 
referral.
Locally this gets referred to ophthalmology[…] and 
our practice is actually within the grounds of the hos-
pital so we’ve got no issues really in terms of adminis-
tering steroids you know before they were seen, they 
would be seen within an hour by an ophthalmolo-
gist. GP7 (10 , M, P) 
The principal and overarching concern relating to 
long-term management was the potential adverse effects 
of glucocorticoid treatment.
Well, it’s a good two years of treatment with steroids 
and all the complications and side effects that they 
carry with them. So, yes, and high doses of it, which 
have been poorly tolerated with the patients. […] 
One patient, she had diabetes, and she was started on 
the steroids, and she was struggling with awful side 
effects from the steroids. She developed, well, lots of 
depressive symptoms. Her blood sugars went all over 
the place. She got a lot of pitting oedema of the legs, 
which was hampering her mobility. She got unsteadi-
ness due to the steroids. GP21 (7, F, S) 
Referral for definitive diagnostic confirmation by a specialist
Specialist referral for definitive diagnostic confirma-
tion was a significant issue for GPs, with referral path-
ways being highly variable across the UK. The specialty 
to which patients with suspected GCA were referred can 
depend on presenting clinical features; however, some of 
this variation reflects local policy and also the regional 
availability of services and specialities.
If their history was suspicious and their inflammato-
ry markers were raised, I would then contact…well 
we’ve had this issue between rheumatology and oph-
thalmology and who to contact, and the line seems to 
be that if they’ve got any visual symptoms then they 
go to ophthalmology and if they haven’t then they go 
to rheumatology. GP13 (5, F, S)
However, in some regions of the UK GPs reported 
that referral pathways were not clear and that specialist 
referral can be challenging.
But, generally, you speak to the on-call medical team, 
and they will advise me to speak to someone else. And 
then they advise me to speak to someone else. So you 
end up making loads of phone calls to try and find 
out which route you go in. GP21 (7, F, S) 
Some participants reported that their local policy 
involved the GP requesting the TAB prior to review by a 
specialist. This often created challenges in itself.
we would try and get a temporal artery biopsy fairly 
promptly. It has been a bit difficult in the past, and 
you know, you’re supposed to get it done within a 
day or two. We traipse round the ophthalmologists, 
who say, ‘No, speak to the vascular people.’ Who say, 
‘No, speak to the general surgeons.’ Well, we tried, 
initially, referring to the ophthalmologist, and they 
just aren’t keen at all […] at the moment we’ve had, 
a general surgery team who have done a temporal 
artery biopsy for us, and the vascular surgeons have. 
GP15 (25, F, P)
Further quotations illustrating the two main themes 
can be seen in table 4.
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DisCussiOn
This is the first study of its kind to explore diagnosis 
and a critical aspect of the care pathway for patients 
with suspected GCA. GCA remains a diagnosis that 
GPs worry about missing. While GPs were comfortable 
with classical presentation patterns, an over-reliance 
on headache to trigger consideration of a diagnosis 
of GCA was evident, with some GPs having limited 
awareness of the full range of symptoms associated 
with GCA.
Table 4 Verbatim quotations from the qualitative study and open responses from the cross-sectional survey
Theme Subtheme Verbatim quotation
Challenges of diagnosis Fear of missing GCA 
and non-specific 
presentation
“an elderly lady who was having headaches and kind of pain around 
her eyes and I’m trying to think what other symptoms she had, general 
misery really. And it sort of came and went and came and went and 
she didn’t really have any visual problems which is good and when you 
said to her, ‘Does it hurt to chew?’ she’d say, ‘Oh yes I think it does’. 
And so yes all of that so in the end I started, I did discuss it with our 
local physicians because just in that situation where you don’t want to 
miss it but on the other hand it doesn’t seem like it’s probably the most 
likely diagnosis. And we got as far as them saying, ‘Well if it’s maybe 
a possibility then go ahead and treat with steroids’, at which point she 
said, ‘No I’m feeling much better thank you’. And that was that until she 
started complaining about it again another few months later.” GP17 (11, 
F, P) 
Initial and ongoing 
treatment and monitoring
Starting treatment “And, certainly, in the past couple of years, we’ve started them on 
steroids first, because, kind of, getting anybody to see them quickly, 
you know, within a day or two, not been possible, which doesn’t seem 
very ideal to me. And we’ve taken the view if it turns out to be wrong, 
we can stop it, but if we don’t start it, there might be a problem before 
they get the biopsy. So that’s, kind of, what we’ve done here.” GP15 
(25, F, P) 
“Yes again just I think in terms of the ongoing management really 
because my experience with another patient, the one that ended up 
with visual disturbance, she sort of then fell between ophthalmology 
and rheumatology without either necessarily taking full responsibility 
for her and actually she was a patient of a partner of mine so he was 
kind of following her up but his experience was that he was piggy in the 
middle really.” GP 6 (20, F, P) 
Expediency of review “you refer them under a two week wait, and it’s not that much of an 
emergency, whereas we all thought you referred them acutely, because 
it was that much of an emergency. So there was a big discrepancy of 
views between what we felt we’d been taught about it, and what other 
people were now doing.” GP23 (12, F, S) 
“I know we, kind of, all get it drummed into us, you know, we should all 
get these things sent in on the day. But I think, well, one of them was 
hanging round for a year, and he didn’t really come to any harm, except 
undue pain and distress that he had. And the other one was hanging 
round for a couple of months, you know. And they were both proved—
as I say, I’m turning the clock back 15 years—but I think they were both 
proven to be temporal arteritis. It maybe isn’t that, kind of, you know, 
you must get them in on the day, as I thought as a medical student, you 
know.” GP22 (15, M, P) 
Challenges with referral 
for definitive diagnostic 
confirmation by specialist
Delays in temporal 
artery biopsy
“The patient that I referred on the NHS, she ended up having a biopsy 
before she saw a consultant rheumatologist. So, yes, it was done that 
way round. The biopsy, of course, came back negative because the 
two week delay before getting it done meant the steroids had treated it.” 
GP21 (7, F, S)
“Local issue regarding whether ophthalmology or vascular surgery will 
perform temporal artery biopsy, reliability of this procedure and steroid 
response whilst waiting for the biopsy.” Participant 2506 (4, 2, P)
Key to participant demographic: GP (n) (qualitative study identifier), Participant (n) (survey identifier) (time qualified as a GP (years), gender 
(Male/Female), seniority/role (S, salaried; P, partner)).
GCA, giant cell arteritis; GP, general practitioner.
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The predominant findings from the cross-sectional 
study, suggest initiation of treatment for patients with 
suspected GCA is not always routine. However, a signif-
icant finding from both the cross-sectional survey and 
qualitative interview study demonstrated that referral 
pathways across the UK vary greatly. Additionally, GPs 
have significant concerns relating to treatment with long-
term glucocorticoids in this patient group, especially in 
conjunction with coexisting multimorbidity.
recommendations
Early identification, referral and initiation of appropriate 
treatment for patients with suspected GCA in general 
practice is critical to prevent complications such as irre-
versible visual loss.1
GPs responding to the survey seem to be over-relying 
on headache when diagnosing GCA. Given that almost 
half of patients do not present with a classical temporal 
headache and that 24% of patients with proven GCA have 
no headache symptoms at all,14 excluding GCA on the 
basis of no headache has the potential to miss a signif-
icant proportion of patients with GCA. However, symp-
toms like headache are common15 with over half of over 
65 year olds having had a headache in the previous 12 
months,16 yet serious pathology is rare in general prac-
tice. Therefore the collective clinical picture needs to be 
considered and has to include the full range of features 
of GCA.
The group of patients with no headache are recognised 
to be at higher risk of permanent visual loss as a result 
of delayed diagnosis.4 17 Therefore, if alternative presen-
tations are not recognised by GPs, they will continue to 
remain a high-risk group. Educating clinicians about 
other presenting symptoms and atypical presentations is 
essential to optimise diagnosis and reduce delays in insti-
gating appropriate treatment and referral, which could 
reduce the potential for visual loss and serious long-term 
complications for this patient group.
A considerable proportion of GPs indicated that they 
would not initiate treatment prior to referral for specialist 
review. From the questionnaire responses, current 
primary care practice would seem to be in line with UK 
recommendations,1 indicating that appropriate doses of 
glucocorticoids, when given, are being prescribed at initi-
ation. Additionally, there seems to be wide variation in 
practice across the UK relating to routes of referral and 
who arranges and performs TAB. Rheumatology remains 
the predominant specialty to whom GPs refer patients 
with suspected GCA, but a range of different specialities 
were identified by participants. These findings may in 
part reflect variations in local policy and the availability 
of specialities regionally. However, it may also identify a 
lack of GP awareness of current national GCA guidelines.
Research into conditions such as rheumatoid arthritis 
highlights that delays in diagnosis can occur at several 
points in the patient journey. These include the patient 
recognising that there is a problem requiring consultation 
(patient level), the patient then getting an appointment 
with the GP, the GP recognising that referral is needed 
and making the referral (GP delay) and the patient 
getting an appointment with the specialist (specialist 
delay).18 These points of delay are also likely to be rele-
vant to patients with GCA. Health promotion could be 
used to improve patients’ awareness of GCA, but may 
be of limited value given the rarity of the condition and 
the wide and non-specific symptoms that patients expe-
rience early in the disease course. However, educational 
strategies for front line clinicians in the early recogni-
tion and management of GCA is critical; although some 
responders indicated that there do not appear to be 
robust fast-track clinical pathways in their local region for 
patients with suspected GCA. Given the relative rarity of 
GCA and variation in its early presentation,14 the poten-
tial for it not being recognised or for initial misdiagnosis 
is high. In regions where TAB is arranged by the GP or 
undertaken before seeing the relevant specialist, there is 
the possibility that a significant amount of unnecessary 
biopsies are being performed especially given that there 
is a great burden of temporal artery biopsies on surgical 
departments with sometimes low yield rates of positive 
biopsy.19 This potentially could be avoided if patients 
with suspected GCA were carefully selected by a clinician 
with significant experience in diagnosing and identifying 
suspected GCA. No participants discussed temporal artery 
ultrasound which can be used to help identify patients 
with GCA5 and this may be because this imaging modality 
where available, is requested by the treating specialist and 
not the GP. Ultrasound techniques may be a preferred 
option for those with significant comorbidities or too frail 
to undergo biopsy but will have to be rapidly available to 
clinicians given the importance of starting glucocorticoid 
treatment in GCA and the rapid effects treatment has on 
typical ultrasound features.6 It is, however, less invasive 
and could be appropriate to being embedded in a care 
pathway for the rapid assessment of GCA in primary care 
to streamline patient pathways to help reduce diagnostic 
confusion, or to better identify patients for TAB20 thereby 
improving outcomes for patients with GCA.21 22 Further, 
studies are being conducted to determine whether avail-
ability and accuracy of temporal artery ultrasound will 
alter requirements for biopsy.23
Delays in assessment for definitive diagnosis creates 
several conundrums surrounding initial treatment. 
Current guidance is clear that treatment should not be 
delayed and should be initiated in patients with suspected 
GCA, although the sensitivity of TAB declines the longer 
treatment has been given before biopsy.24 High dose 
glucocorticoid treatment may have a significant impact 
on symptoms by the time they present to the reviewing 
specialist and therefore definitive diagnosis for patients 
who have had a negative biopsy can become extremely 
challenging. However, an accurate diagnosis is critical and 
a decision to delay treatment in patients with true GCA 
could result in visual loss. Equally, a decision to continue 
treatment in someone who does not truly have GCA will 
expose that patient to an inappropriate treatment course 
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(and therefore associated potential adverse effects) of 
glucocorticoids, as treatment often continues for many 
patients, despite a negative TAB.24
Our quantitative data suggested that over one-third 
of participants would not initiate treatment prior to 
referral despite UK national guidance which advises the 
immediate initiation of high dose glucocorticoids.1 This 
represents an area where further education to encourage 
the immediate initiation of treatment could improve 
outcomes for patients with GCA. However, not initiating 
treatment may be in part due to variations in local or 
practice policy.
strengths and limitations of this study
The predominant strength of this study is the use of a 
multimethods approach, which has allowed the iden-
tification of significant challenges relating to GCA 
management in primary care and subsequent in-depth 
exploration of those issues.
The main weakness in this study was the suboptimal 
response rate and therefore the potential lack of gener-
alisability of our findings. However, a response rate 
of 25% is comparable to similar musculoskeletal GP 
surveys conducted in the same setting.25 Additionally, 
while low response rates may increase the possibility of 
bias, responder demographics of the questionnaire study 
relating to age, gender and GP role were comparable to 
national GP demographics.26 The standard limitations 
of telephone interviews also apply in this study. While 
such interviews enabled participants to be interviewed 
from a wide geographical area and therefore generate 
rich data on differing local management policies, they 
may reduce rapport and non-verbal communication. 
However, the questions used in the topic guide were 
highly clinical and therefore the lack of rapport building 
or visual cues is unlikely to have significantly impacted on 
data quality, as participants were not revealing personal 
details. TH undertook all of the qualitative data analysis 
which potentially could impact on theme development 
due to personal preconceptions and misinterpretations. 
However, an inter-rater analysis was undertaken to ensure 
concordance of themes identified. This did not show any 
difference between raters. Finally, there is the potential 
for discrepancies between reported behaviour and actual 
behaviour, this is inherent in both survey and interview 
studies.
COnClusiOn
An increased focus on education and awareness of GCA 
(given its rarity and the range of presenting features 
including more subtle features such as limb claudication, 
constitutional symptoms, vascular bruits, asymmetry of 
pulses and or blood pressure, anaemia1) may aid better 
identification of patients with potential GCA. However, 
significant challenges around GCA remain in primary 
care, some of which need to be addressed in conjunction 
with specialist settings. National guidelines suggest that 
GCA is a medical emergency and so treatment should 
not be delayed. However, as yet there are no UK national 
standardised fast-track referral/care pathways enabling 
rapid referral of patients suspected of having GCA yet 
fast-track pathways have been shown to potentially reduce 
the complication of sight loss in GCA.21 This study iden-
tifies wide variations in the way that patients are initially 
managed across the UK and therefore adopting stan-
dardised fast-track services for patients with suspected 
GCA could enable effective and accurate diagnosis 
and management and therefore improve outcomes for 
patients with GCA.
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